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Abstract 
Objective
To evaluate psychopathological status and stress level from a sample with SLE; compare mental functioning and stress 
levels between women with SLE and healthy women; determine whether disease duration, disease activity, cumulative 
organ damage and stress have an influence on psychopathological symptoms in SLE patients; and evaluate whether 
perception of stress is related to SLE severity. 
Methods
We conducted a cross-sectional study of 425 participants; 202 women with SLE, with an average age (SD) of 36.61 (10.15), 
and 223 healthy women, with age-matched controls. The assessment included the clinical characteristics (disease 
duration, SLE activity, cumulative organ damage, pharmacotherapy), the Symptom Checklist-90-Revised (SCL-90-R) 
and the Perceived Stress Scale. Descriptive, comparative, univariate and multivariate analysis were performed. 
Results
SLE patients showed psychopathological alterations in the somatisation, obsessive-compulsive and positive discomfort 
subscales of SCL-90-R. Women with SLE reported significantly higher scores on the psychopathological dimensions and 
perceived stress compared to healthy women, except for paranoid ideation. Disease duration, SLE activity, cumulative 
organ damage, and perceived stress were shown to be significant predictors of psychopathological manifestations, 
explaining a range, between 20 and 43%, of variance across SCL-90-R dimensions. Moreover, perceived stress was 
related to SLE activity, after controlling for psychopathological dimensions.
Conclusion
The psychopathological manifestations in SLE appeared to be influenced by perceived stress, disease duration, disease 
activity and cumulative organ damage. In turn, perceived stress was associated with disease severity. This knowledge may 
contribute to a more comprehensive perspective of these manifestations in the SLE population in the clinical setting.
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Introduction
Systemic lupus erythematosus (SLE) 
is regarded as a chronic (long-term), 
multisystem, connective-tissue disease, 
characterised by an alteration in the im-
munological response (1-2). Its clinical 
course is usually unpredictable, with 
exacerbations and periods of remission 
(3). During the course of the disease, all 
tissues and organs may be potentially 
impaired, occasionally irreversibly 
(4). The SLE disease course presents a 
broad spectrum of clinical symptoms, 
a set of immunological alterations and 
specific anatomopathological charac-
teristics (5). Common manifestations 
include inflammation, swelling (involv-
ing the skin and joints), pain, fatigue, 
rashes, arthritis, stiffness, lassitude, 
weight loss, hair loss, anemia and fever, 
appearing even in periods of disease la-
tency (1, 6-8). Consequently, SLE may 
affect several aspects of patients’ daily 
lives, leading to impairment of quality 
of life and patient functioning (3-4, 7). 
SLE clinical characteristics include 
psychopathological manifestations that 
can be present in almost 50% of the 
population during the disease course 
(9-10). These manifestations are even 
suggested to be an integral part of the 
SLE process (11). Symptoms of anxi-
ety and depression have been shown 
to be related to poorer quality of life 
and work disability in these patients 
(12-13). However, the prevalence of 
psychopathological manifestations var-
ies broadly in this population across 
the studies (14). This wide variation 
is mainly the result of methodological 
deficiencies. Research into this topic 
has usually employed poor comparison 
groups, or lacked them completely, has 
failed to use standardised measures, or 
has used small, unrepresentative and 
unbalanced samples (14-15). 
The literature has emphasised the im-
portance of medical components in the 
disease course for SLE patients. How-
ever, although these are of considera-
ble importance, psychological aspects, 
such as stress level or psychopatho-
logic status, have been disregarded and 
neglected (6, 8, 16-17). Several studies 
highlight the relevance of psychologi-
cal factors in autoimmune pathologies, 
and these factors have been considered 
relatively independent from physical 
findings (18-20). Some investigations 
have reported that the stress level could 
cause a worsening of the disease course 
(6, 17, 21-22). Da Costa et al. (3) con-
cluded that the stress level is the most 
important short-term factor of func-
tional disability in SLE patients. On the 
other hand, some disease parameters, 
such as disease activity or cumulative 
organ damage, have been demonstrat-
ed to be independent components of 
health status among these patients (18). 
Several researchers have pointed out 
the need for additional studies, which 
may elucidate the critical variables 
for psychiatric symptoms in SLE pa-
tients (10-11). Nevertheless, although 
SLE patients seem to present psycho-
pathological disorders, no studies have 
investigated the predictive factors of 
these manifestations in the SLE popu-
lation. Furthermore, despite the clinical 
importance of the clinical characteris-
tics and perceived stress on SLE, to our 
knowledge, the role of these factors re-
garding psychopathological manifesta-
tions remains uncertain.
Therefore, the objectives of the present 
study were: 1) to compare the psycho-
pathological status and the stress levels 
between women with SLE and healthy 
women; 2) to determine whether dis-
ease duration, disease activity, cumula-
tive organ damage and perceived stress 
have an influence on psychopathologi-
cal levels in SLE patients; 3) to evalu-
ate whether the perception of stress is 
related to SLE severity.
Materials and methods
Study population and design
This is an observational, cross-sectional 
study. The total sample consisted of 425 
women, living in Andalusia (Spain), 
with an average age of 36.20 years 
(SD=10.62) in an age range between 18 
and 78 years. Participants were divided 
into two groups, people with SLE (SLE 
patients group, n=202) and healthy 
people (healthy control group, n=223). 
All participants with SLE were patients 
at the Systemic Autoimmune Disease 
Units, from two Public Health Service 
hospitals in the Autonomous Commu-
nity of Andalusia (Spain). The healthy 
control group was recruited in a con-
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secutive manner from relatives of SLE 
patients and workers from the hospital 
and university, so they tend to share a 
similar socioeconomic environment. 
The inclusion criteria for both groups 
were: being a woman and having a 
level of education higher than elemen-
tary. The SLE group also had to meet 
at least four of the American College 
of Rheumatology criteria for SLE (23). 
Exclusion criteria were: having a se-
vere cardiovascular disease, having a 
history of another autoimmune disease, 
having severe neurological damage 
and abusing alcohol or other drugs. All 
participants gave their signed informed 
consent to participate in this study. Pro-
cedures followed standards from the 
responsible Human Bioethics commit-
tee and the Helsinki Declaration. 
Information collected
A specific demographic questionnaire 
(age, education, civil status) was cre-
ated for this study. Clinical data of SLE 
such as disease duration (years), the 
SLE activity, cumulative organ damage 
and pharmacotherapy (corticosteroid 
therapy dose, corticotherapy, antimalar-
ial agents, psychotropic and immuno-
suppressant drugs) were collected. Psy-
chopathological manifestations (mental 
functioning) and perceived stress level 
were evaluated for both groups by us-
ing the Symptom Checklist-90-Revised 
and Perceived Stress Scale, respective-
ly. All measures were validated instru-
ments for the Spanish population. 
The SLE Disease Activity Index 
(SLEDAI) 
The total SLEDAI score shows the 
level of activity of the disease over the 
last ten days, ranging from 0 (no activ-
ity) to 105 points (maximum activity) 
(24-25). 
Systemic Lupus International 
Collaborating Clinics/American 
College of Rheumatology 
(SLICC/ACR) Damage Index
The SLICC/ACR evaluates cumulative 
organ damage caused by the disease 
itself or complications after therapy 
interventions. The total score ranges 
from 0 (no damage) to 48 points (maxi-
mum damage) (26-27).
The Symptom Checklist-90-Revised 
(SCL-90-R)
The SCL-90-R is a 90-item self-report 
symptom inventory that evaluates 
mental functioning/psychological dis-
tress. This instrument comprises nine 
primary symptom dimensions and 
three summary scores, determined as 
global scores. The principal symptom 
dimensions are categorised as soma-
tisation, obsessive-compulsive, inter-
personal sensitivity, depression, anxi-
ety, hostility, phobic anxiety, paranoid 
ideation and psychoticism. The global 
measures result in the global sever-
ity index (GSI), the positive symptom 
distress index (PSDI) and the positive 
symptom total (PST). The total score 
ranges from 0 (not at all) to 4 points 
(extremely), considering how patients 
feel or how the specific problem has 
bothered them in the last week (28-29).
Perceived Stress Scale (PSS)
This tool is a self-report questionnaire 
that assesses the perceived stress level 
over the last four weeks. This scale 
has fourteen items with a five-point 
frequency response scale, ranging 
between 0 (never) to 4 points (very 
often). Higher scores are interpreted 
as a higher level of perceived stress. 
The PSS has demonstrated adequate 
reliability (internal consistency with 
a Cronbach alpha of 0.81), and good 
concurrent validity and sensitivity in 
the Spanish population (30).
Procedure
The procedure for collecting all the 
study information was similar to what 
was published previously by Peralta-
Ramírez et al. (16). The first contact 
was with the internist at the outpatient 
clinic for autoimmune disease. Poten-
tial participants that met the inclusion-
exclusion criteria were recruited. All 
these patients were informed about the 
study objectives and they were invited 
to participate (response rate of 89%). 
In the first session, full details on the 
study were provided and participants 
were asked to sign the written consent 
form. Then, investigators collected the 
demographic and clinical information, 
and the psychopathological and stress 
evaluation was completed. The study 
was conducted between March 2013 
and January 2016. The healthy (control) 
group was recruited in a consecutive 
manner. This study was approved by the 
Human Bioethics Committee – Hospital 
Virgen de las Nieves (Granada, Spain).
Statistical analysis
The analyses for this study were per-
formed using SPSS software, v. 20.0. 
The total sample was divided into 
two groups (SLE and control group). 
A descriptive analysis was performed 
and a normal distribution of variables 
was confirmed with the Kolmogorov 
Smirnov test. The Box-Cox transfor-
mation was performed for non-normal 
distributed variables. The Levene’s test 
was used to evaluate the equality of var-
iances. Independent t-tests and χ2 tests 
were used to assess differences between 
the SLE group and the control group. 
We performed twelve multiple regres-
sion analyses to evaluate which disease 
and psychological outcomes best ex-
plain the scores on the SCL-90-R for 
SLE patients. The dependent variables 
were the scores on each of the subscales 
of the SCL-90-R inventory. The inde-
pendent variables were stress scores, 
disease duration, SLEDAI and SLICC. 
A Multivariate analysis of covariance 
(MANCOVA) was performed to evalu-
ate whether the level of perceived stress 
and SLE severity were related, while 
correcting for the psychopathological 
variables. The MANCOVA was carried 
out using the level of perceived stress 
(perception of stress vs. no perception 
of stress) as independent variables, and 
SLEDAI and SLICC (disease severity) 
as dependent variables. The SLE sam-
ple was divided into two groups of per-
ceived stress, taking the mean for the 
Spanish population (25 points on PSS 
scale). All psychopathological dimen-
sions that were found to be clinically 
significant in the SLE patients group 
were introduced as covariates.  
Results
Description of demographics 
and clinical data, psychopathological 
symptoms, and perceived stress
of the SLE group
The average age of the subjects in the 
SLE sample is 36.61 (SD=10.15) years. 
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From this sample, 80.6% of patients 
scored 0 points on the SLICC index, 
showing no cumulative organ damage. 
Specifically, five SLE patients suffered 
from neuropsychiatric SLE, three from 
renal damage and fifteen from neuro-
logical damage. They reported scores 
above 70 points in the subscales of so-
matisation (M=71.21), obsessive-com-
pulsive (M=72.04) and positive symp-
tom total index (M=71.98), indicat-
ing clinical psychopathology in these 
dimensions. From the SLE sample, 
64.9% presented clinical somatisation, 
65.7% obsession-compulsion, 48.5% 
interpersonal sensitivity, 45.3% de-
pression, 54.5% anxiety, 47.5% hostil-
ity, 34.7% phobic anxiety, 45.5% para-
noid ideation and 55.4% psychoticism. 
In addition, 18% showed a clinical 
alteration in the global severity index, 
32.7% in the positive symptom distress 
index and 64.9% in the positive symp-
tom total. The mean score of perceived 
stress was 26.37 (SD=9.31) points. The 
remaining descriptive information is 
shown in Tables I–III.
Differences between the SLE group 
and the healthy control group for 
sociodemographic variables
In the comparison between groups 
(SLE/control group) for the main so-
ciodemographic variables, there were 
no differences between groups, except 
for level of education. The healthy 
women’s control group demonstrated a 
higher educational level than the SLE 
group. Means, SD and percentages of 
sociodemographic variables, and be-
tween-group comparisons are shown in 
Table I. 
Differences between the SLE group 
and the healthy control group for 
psychopathological dimensions 
and perceived level of stress
In contrast to SLE patients, healthy 
participants showed significantly low-
er scores across all dimensions of the 
SCL-90-R, except for the paranoid 
ideation subscale. There were also sig-
nificant differences between groups 
for the perceived stress scale. Table III 
shows the mean psychopathological 
and perceived stress in the SLE sam-
ple compared with the control group. 
A comparison between the two groups 
for the psychopathological profile is 
also depicted in Figure 1.
Effect of disease parameters 
and perceived level of stress on 
psychopathological dimensions 
in SLE patients 
The results revealed that the disease du-
ration, disease activity, cumulative or-
gan damage and perceived stress scores 
were significant predictors of all dimen-
sions from the SCL-90-R inventory in 
the SLE sample. The disease duration, 
PSS and SLEDAI scores were associat-
ed with somatisation, predicting almost 
25% of the total variance in this dimen-
sion. The same clinical and psychologi-
cal variables were also associated with 
the obsessive-compulsive and inter-
personal sensitivity dimensions, and a 
positive discomfort index score, pre-
dicting 32%, 20% and 37% of the to-
tal variance, respectively. The PSS and 
SLEDAI scores predicted almost 42% 
of the variance for depression and 16% 
for the global severity index; the PSS 
and disease duration scores explained 
27% of anxiety, 22% of psychoticism 
and 27% of the positive symptom total; 
the PSS and SLICC scores explained 
22% of hostility; and the PSS predicted 
8% of phobic anxiety. In general, the 
perceived level of stress was a partial 
predictor for all dimensions of the SCL-
90-R inventory (see Table IV).
Relationship between perceived 
level of stress and lupus severity 
while controlling for psychopathology 
in SLE patients 
The results from the MANCOVA anal-
yses, controlling for psychopathologi-
cal dimensions, indicate that stressed 
SLE patients and non-stressed SLE 
patients differ significantly regarding 
disease activity (SLEDAI) (F=4.628, 
p=0.011). After introducing the psycho-
pathological dimensions as covariates, 
the subgroup of SLE patients reporting 
Table I. Mean (SD), percentages and level of significance of differences between SLE and 
healthy control group for sociodemographic variables (n=423).
 LES group Control group
 (n=202)  (n=223)  
Characteristics Mean (SD)/ Mean (SD)/ T/Chi-square p- value
 Percentage (%)  Percentage (%) 
Age 36.61 (10.15) 35.82 (11.05) 0.768 0.443
Educational level    
Primary school 33.5 % 11.4 % 38.50 0.001
Secondary school 40.1 % 31.3 %  
Associate’s degree 26.4 % 57.3 %  
Civil status    
Single 30.8 % 41.7% 4.99 0.082
Married  61.5 % 44.4 %  
Widowed/ separated/ divorced 7.7 % 13.9 %  
Table II. Clinical outcomes of SLE group (n=202).
Clinical outcomes  Mean (SD) Percentage (%)
Disease duration 10.15 (8.34) 
SLEDAI 2.28 (2.78) 
SLICC. Range (0 – 6) 0.34 (0.91) 
SLICC = 0   80.60%
SLICC > 0   19.40%
Pharmacotherapy  
Dose corticosteroid therapy 3.66 (3.68) 
Corticotherapy    53.44 %
Antimalarial agents   12.87 %
Psychotropic drugs   5.45 %
Immunosuppressive agents   18.81 %
SLE: systemic lupus erythematosus; SLEDAI: SLE Disease Activity Index; SLICC: Systemic Lupus 
International Collaborating Clinics. 
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stress had significantly higher levels of 
disease activity if compared with SLE 
patients not reporting stress (M=2.44 
vs. M=2.01, respectively). However, 
there was no multivariate difference for 
cumulative organ damage between the 
two groups; both groups revealed simi-
lar levels of cumulative organ damage 
(SLICC). 
Discussion
The objectives of this research were to 
compare mental functioning and stress 
levels between women with SLE and 
healthy women, to determine whether 
several disease parameters and per-
ceived stress have an influence on psy-
chopathological levels in SLE patients, 
as well as evaluating whether stress and 
disease severity are related. The results 
have shown that the SLE sample from 
this study seems to shows a specific 
psychopathological profile, character-
ised by manifestations of somatisation, 
obsessive-compulsive symptoms and 
high scores on the positive symptom 
total index. This profile indicates that 
SLE subjects could be at clinical risk 
of suffering alterations for these dimen-
sions. When SLE patients and healthy 
participants were compared, the SLE 
sample showed significantly higher 
levels for the variables of somatisa-
tion, obsessive-compulsive, interper-
sonal sensitivity, depression, anxiety, 
hostility, phobic anxiety, psychoticism 
and perceived stress. Several disease 
parameters and the level of perceived 
stress were associated with the psycho-
pathological status of SLE patients. In 
turn, perception of stress and activity 
disease were related (while controlling 
for psychopathology), with higher dis-
ease severity scores among SLE pa-
tients that reported stress.
On the other hand, the level of cumula-
tive organ damage was low in the SLE 
sample, probably because the SLICC is 
an index of organ damage, even when 
there are activity outbreaks. Close fol-
low-up and monitoring of patients al-
lows an early therapeutic approach to 
prevent involvement or impairment of 
the vital organs. Classically renal (and 
neurological) involvement conditioned 
disease prognosis. However, current 
therapeutic options can contain this. The 
most superior treatments include the 
use of corticosteroids. These drugs are a 
classic treatment but their use has been 
modified over the years, with greater 
control over doses and how long they 
are used to avoid long-term side effects 
on classic cardiovascular risk factors 
(diabetes, hypertension, hypercholes-
terolaemia, abdominal obesity), among 
others. Furthermore, immunosuppres-
sants are also used early on to decrease 
the doses of corticosteroids and to help 
control the activity. All this can help re-
duce functional alterations in the organs 
due to persistent SLE activity.
To our knowledge, this is the first study 
evaluating the association between the 
disease parameters, perceived stress, 
and psychopathological status of SLE 
Table III. Mean (SD) and level of significance of differences between SLE and healthy 
control group for mental functioning (SCL-90-R) and stress level (PSS) (n=423).
Outcomes  SLE group   Control group T p-value
  (n=202)    (n=223) 
 Mean  SD Mean  SD  
Mental functioning      
Somatisation  71.22a 26.27 52 23.3 7.92 0.001
Obsessive-compulsive  72.04a 26.06 56.20 26.51 6.17 0.001
Interpersonal sensitivity  61.72 30.48 54.32 27.65 2.60 0.010
Depression  61.72 28.69 45.42 25.66 6.12 0.001
Anxiety  66.01 25.83 50.76 25.78 6.06 0.001
Hostility  61.69 28.05 47.83 25.01 5.34 0.001
Phobic anxiety  47.04 36.12 34.36 29.49 3.93 0.001
Paranoid ideation  55.38 33.96 51.51 28.70 1.26 0.210
Psychoticism  63.29 33.79 46.38 30.96 5.45 0.001
GSI  40.66 28.11 31.84 24.95 3.38 0.001
PST  71.98a 28.09 54.97 23.88 5.30 0.001
PSDI  52.43 27.31 38.91 28.24 6.28 0.001
Level of stress      
PSS 26.37 9.31 20.95 7.75 6.40 0.001
SLE: systemic lupus erythematosus; GSI: Global Severity Index; PST: Positive Symptom Total; PSDI: 
Positive Score Discomfort Index; PSS: Perceived Stress Scale. a Standard T scores for subscales of the 
SCL-90-R higher than 70 points. Statistical significance p<0.05. 
Fig. 1. Mean scores for the psychopathological dimensions (SCL-90- R) and comparison between 
groups (SLE patients/healthy control group).
SOM: somatization; OBS-COMP: obsessive-compulsive; INT SEN: interpersonal sensitivity; DEP: 
depression; ANX: anxiety; HOS: hostility; PHO ANX: phobic anxiety; PAR IDE: paranoid ideation; 
PSYCHO: psychoticism; GSI: global severity index; PST: positive symptom total; PSDI: positive 
symptom distress index.
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patients. The higher levels of psycho-
logical alteration in the SLE group 
could be explained by the uncertainty 
of the disease course, medical symp-
toms, therapy, pain, and the loss of 
function and personal autonomy. These 
results contrast with other investiga-
tions, reporting that SLE patients seem 
to have the same level of depression, 
perceived stress, tension or anger as 
the subjects from the control groups 
(11, 21, 31). These findings also show 
that PSS, SLEDAI and SLICC scores, 
as well as the disease duration of SLE 
patients, have a significant influence 
on the psychopathological manifesta-
tion of patients with SLE. These vari-
ables explained more than 20% of the 
variance of somatisation, interpersonal 
sensitivity, anxiety, hostility, psychoti-
cism and positive symptom total; more 
than 30% of the obsessive-compulsive 
and positive discomfort index score 
variances; and 42% for depression. 
However, the associations were cross-
sectional; hence, we cannot determine 
the cause and the effect.
Specifically, the perceived level of 
stress appeared to be associated with 
all of the psychopathological dimen-
sions in patients with SLE. Therefore, 
perceived stress could have an impact 
on psychopathological manifestations 
or vice versa. Although the mecha-
nisms involved in these associations 
cannot be determined from this study, 
some speculation is possible. The 
chronic and unpredictable nature of 
the disease could lead patients to live 
with a possible and sudden disruption 
of independency, autonomy and health. 
Paralleling this explanation, Peralta-
Ramírez et al. (16) reported that daily 
stress is also a cognitive function-
ing predictor. They claim that stress 
may impair visual memory, fluency 
and attention-related resources. Im-
pairment of these cognitive functions 
could influence brain interpretations 
and general mental functioning. Other 
authors report that stress, evaluated 
by registering major life events, such 
as a job loss or a divorce, and hassles 
such as time pressure or financial wor-
ries, contributes to psychopathologi-
cal status (15). However, contrary to 
this assumption, other findings point 
to psychopathology, which affects the 
perception of stress. In the study con-
ducted by Palagini et al. (32), these 
authors included an anxiety and de-
pressive symptoms evaluation, assess-
ing its influence on perceived stress, us-
ing the same scale as the present study. 
This research concluded that insomnia, 
stress and psychopathology (especially 
depression) were related. 
Moreover, SLE patients that reported 
stress showed significantly higher lev-
els of disease activity (when psychopa-
thology was controlled), highlighting 
the importance of the perceived level of 
stress on disease severity (3, 6, 17, 33). 
In the literature, stress is revealed to be a 
modifiable risk factor that is involved in 
the onset, the course and the exacerba-
tion of several chronic diseases. In fact, 
many SLE patients report that stressful 
life events are linked to exacerbations 
of SLE symptoms (3). Furthermore, a 
high percentage of SLE patients seem 
to perceive a worsening in their clinical 
symptomatology caused by the effects 
of daily stress (6). Several researchers 
such as Peralta-Ramírez et al. (6), Ad-
ams et al. (22) and Pawlack et al. (17) 
have shown that daily stress, and not 
stressful life events, may worsen the 
subjective clinical symptomatology of 
SLE. Therefore, perceived stress plays 
a central role in contributing to a more 
comprehensive perspective of SLE 
symptoms.
It was shown that disease duration was 
related to the somatisation, obsessive-
compulsive, interpersonal sensitivity, 
anxiety, psychoticism, positive symp-
tom total dimensions, and the posi-
tive symptom total index. This can be 
interpreted as: the higher the number 
of years with the disease, the lower 
the psychopathological manifestation 
scores, probably because SLE patients 
present an emotional adaptation to 
chronic disease when they must cope 
Table IV. Final lineal multiple regression model of predictive associated factor to mental 
functioning (SCL-90-R) in women with SLE (n=202).
Dependent V Predictor V R2 R2 corrected Beta T p-value
Somatisation Disease duration 0.254 0.235 -0.189 -2.680 0.008
 PSS   0.403 5.638 0.001
 SLEDAI   -0.139 -0.139 0.044
Obsessive-compulsive Disease duration 0.339 0.322 -0.198 -2.987 0.003
 PSS   0.479 7.134 0.001
 SLEDAI   -0.130 -2.002 0.047
Interpersonal sensitivity Disease duration 0.218 0.198 -0.264 -3.658 0.001
 PSS   -0.277 2.794 0.001
 SLEDAI   0.171 2.375 0.019
Depression PSS 0.429 0.415 0.607 9.725 0.001
 SLEDAI   -0.129 -2.143 0.034
Anxiety Disease duration .291 .273 -0.201 -2.929 0.004
 PSS   0.442 6.344 0.001
Hostility PSS 0.239 0.220 0.418 5.799 0.001
 SLICC   0.160 2.261 0.025
Phobic anxiety PSS 0.099 0.077 0.215 2.737 0.007
Psychoticism Disease duration 0.239 0.220 -0.214 -3.012 0.003
 PSS   0.384 5.332 0.001
GSI PSS 0.181 0.160 0.312 4.168 0.001
 SLEDAI   0.250 3.474 0.001
PST  Disease duration 0.268 0.268 -0.166 4.168 0.017
 PSS   -2.413 3.474 0.001
PSDI  Disease duration 0.386 0.371 -0.233 -3.643 0.001
 SLEDAI   -0.139 -2.222 0.028
 PSS   0.504 7.790 0.001
V: variable; SLE: systemic lupus erythematosus; GSI: Global Severity Index; PST: Positive Symptom 
Total; PSDI: Positive Score Discomfort Index; PSS: Perceived Stress Scale; SLEDAI: SLE Disease 
Activity Index; SLICC: Systemic Lupus International Collaborating Clinics.
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with the daily symptoms (18, 34). In 
the research carried out by Purandare et 
al. (10), the SLE sample with psycho-
pathological manifestations was similar 
to those who presented no psychiatric 
disorders regardless of the disease dura-
tion and the disease activity. However, 
these authors explained that these find-
ings were due to the small sample size 
and low statistical power (10). 
The disease activity also seems to pre-
dict the psychopathological status for 
dimensions such as interpersonal sen-
sitivity, somatisation, obsessive-com-
pulsive, depression, positive symptom 
total, and global severity index. Along 
this line, prior research suggests that 
disease activity may influence psycho-
logical status in the acute phase, caus-
ing mild psychiatric disorders (14). In 
contrast, some findings exploring the 
link between depressive symptoms 
and SLE patients’ disease activity have 
been inconclusive (18, 35). Seguí et al’s 
study (14) and other researchers have 
claimed that the psychopathological 
symptoms are similar to what would be 
expected in other populations coping 
with similar stress (14, 31, 36). Our re-
sults show that specific SLE course fac-
tors, such as disease duration or disease 
activity were associated with psycho-
pathological manifestations. However, 
in turn, disease severity seems to be re-
lated to perceived stress, as previously 
discussed. Moreover, these results also 
showed that cumulative organ damage 
only explained part of the variability of 
the hostility dimension, probably indi-
cating frustration and feelings caused 
after becoming aware of impairment to 
vital functions. Conversely, the study 
performed by Baker et al. (37) found 
no statistical correlation between psy-
chopathology and the severity of SLE 
or the degree of renal damage. 
Finally, it should be discussed that the 
major difficulty regarding the evalu-
ation of neuropsychiatric symptoms 
lies in their attribution to the underly-
ing disease activity or to a concomi-
tant psychopathology secondary to the 
chronic disease or even to a primary 
comorbidity, especially for mild psy-
chiatric symptoms. The attribution of 
these symptoms to the SLE disease 
(termed primary neuropsychiatric SLE) 
or to comorbidities/therapy complica-
tions, remains challenging because of 
multiple problems regarding the avail-
able diagnostic tests. Hence, to fa-
cilitate physicians’ evaluation of these 
symptoms, several models have been 
proposed, such as SLICC or the Italian 
Study Group on neuropsychiatric SLE. 
The study by Fanouriakis et al. (38) 
evaluated these models and compared 
them against the clinical judgment of 
physicians with experience in SLE. 
These authors concluded that using 
the SLICC model as a “standard” may 
lead to problems. This instrument only 
seems to attribute a small number of 
neuropsychiatric symptoms to SLE. For 
these reasons, the judgment of an expe-
rienced physician should also be con-
sidered. However, this judgment should 
not be relied upon solely, due to pos-
sible subjectivity and different levels 
of expertise among physician (38). In 
our study, the investigator that admin-
istrated the SLICC tool was a physician 
with 20 years of experience in evaluat-
ing and monitoring SLE patients. 
When considering the findings of the 
present study, there are some limita-
tions. Firstly, the cross-sectional nature 
of this study makes it difficult to obtain 
conclusive results regarding the direc-
tionality of the relationships. It is pos-
sible that psychopathological problems 
are the cause of the impairment in the 
disease parameters and of the higher 
levels of perceived stress, or vice versa. 
Secondly, groups from this study were 
not statistically equal at an educational 
level. This difference could introduce 
a bias; therefore, the results should 
be interpreted with caution. Thirdly, 
psychopathological aspects were re-
lated to an increase in stress perception 
but we have not controlled for coping 
strategies. These strategies should be 
included in future studies, consider-
ing the effect that they might have on 
the relationship between stress and 
psychopathological symptoms in SLE 
patients. 
In conclusion, the findings highlight 
that the SLE sample is at risk of suffer-
ing psychopathological alterations, es-
pecially in dimensions such as somati-
sation, obsessive-compulsive and posi-
tive symptoms. Comparisons between 
SLE patients and the healthy control 
group show statistical differences in 
the psychopathological status, with the 
SLE group reporting lower scores. In 
turn, psychopathological manifesta-
tions seem to be partially influenced by 
the perceived stress, disease duration, 
disease activity and cumulative organ 
damage, and disease severity by per-
ceived stress. In general, these findings 
may contribute to a more comprehen-
sive understanding of the risk factors of 
psychopathological alterations in SLE 
patients. These results also draw atten-
tion to the need for clinicians to include 
psychological components as part of 
more comprehensive patient monitor-
ing. This information would improve 
the understanding of medical and psy-
chological components involved in 
SLE disease. Interventions from the 
health professional teams could lead to 
adequate levels of stress and decreased 
psychopathological symptomatology. 
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